Results 21 to 30 of about 25,067 (205)
, 2021 To better understand the mechanism of PARPi resistance, two olaparib-resistant SUM159 and MDA468 cells were established by chronically exposing to olaparib. Olaparib-resistant SUM159 and MDA468 cells displayed 5-fold and 7-fold more resistant relative to
Gen Sheng Wu (11837173) +1 more
core +1 more source
Research, 2023 Platinum-based chemotherapy remains the main systemic treatment of ovarian cancer (OC). However, the inevitable development of platinum and poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) resistance is associated with poor outcomes ...
Yangyang Li +7 more
doaj +1 more source
Is a Clinical Trial With a Non-Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK. [PDF]
Clin Pharmacol TherAlthough physiologically based pharmacokinetic (PBPK) modeling is increasingly being used to support oral drug formulation bridging, the acceptance by regulatory agencies is low. One of the primary concerns is the absence of clinical pharmacokinetic (PK) data from a non‐bioequivalent (non‐BE) batch during model validation.
Dong J +6 more
europepmc +2 more sources
Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress
Frontiers in Oncology, 2022 The poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) Olaparib is a widely used targeted therapy for a variety of solid tumors with homologous recombination deficiency (HRD) caused by mutation of BRCA1/2 or other DNA repair genes.
Tao Han +13 more
doaj +1 more source
Cells, 2020 In highly metastatic tumors, vasculogenic mimicry (VM) involves the acquisition by tumor cells of endothelial-like traits. Poly-(ADP-ribose) polymerase (PARP) inhibitors are currently used against tumors displaying BRCA1/2-dependent deficient homologous ...
Mónica Fernández-Cortés +2 more
doaj +1 more source
Defective DNA repair mechanisms in prostate cancer: impact of olaparib [PDF]
, 2017 Francesca De Felice,1 Vincenzo Tombolini,1 Francesco Marampon,2 Angela Musella,3 Claudia Marchetti3 1Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Rome, 2Department of Biotechnological and Applied Clinical
Musella A +5 more
core +1 more source
The PARP-1 inhibitor Olaparib causes retention of γ-H2AX foci in BRCA1 heterozygote cells following exposure to gamma radiation [PDF]
, 2013 This article is made available through the Brunel Open Access Publishing Fund. Copyright © 2013 Emma C. Bourton et al. This is an open access article distributed under the Creative Commons Attribution Li-cense, which permits unrestricted use ...
Bourton, EC +4 more
core +1 more source
BMC Cancer, 2021 Background The advances in colorectal cancer (CRC) treatment include the identification of deficiencies in Mismatch Repair (MMR) pathway to predict the benefit of adjuvant 5-fluorouracil (5-FU) and oxaliplatin for stage II CRC and immunotherapy ...
Helena de Castro e Gloria +6 more
doaj +1 more source
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer [PDF]
, 2021 Preclinical studies have shown synergistic effects when combining PARP1/2 inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models. After a formulation change of olaparib from capsules to tablets, we initiated a dose finding study of olaparib ...
Marchetti, Serena +10 more
core
, 2020 Objective: Olaparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1, 2, and 3 with potential activity in endometrial cancer (EC). Methods: In this window-of-opportunity trial, women with operable type 1 EC received olaparib oral tablets ...
Romero, Ignacio +2 more
core +1 more source